# SUPN — Supernus Pharmaceuticals · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** SUPN  
**Sources:** 25  
**Published:** 2026-10-27  
**Canonical:** https://app.k3vl4r.com/research/deep-research-supn-supernus-pharmaceuticals-catalysts-narrative-risks-9647

---

## Supernus Pharmaceuticals (SUPN) — Research Snapshot (as of 2026-10-27)

**Context:** Supernus is a mid-cap CNS-focused biopharmaceutical company (Nasdaq: SUPN), market cap ~$2.4B, trading near ~$40–41, with a portfolio of eight marketed products and a late-stage pipeline. [[18]](https://stockanalysis.com/stocks/supn/), [[19]](https://finance.yahoo.com/quote/SUPN/) The dominant theme of the last quarter is the pending all-stock merger with Indivior, alongside an upcoming Q3 earnings print.

---

### Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-supn-supernus-pharmaceuticals-catalysts-narrative-risks-9647 (free to sign up)._
